AVI BIOPHARMA INC (AVII) is a publicly traded company in the Unknown sector. Across all available filings, 20 corporate insiders have executed 161 transactions totaling $14.0M, demonstrating a bearish sentiment with -$6.7M in net insider flow. The most recent transaction on Apr 24, 2012 involved a transaction of 81,666 shares valued at $0.
No significant insider buying has been recorded for AVII in the recent period.
No significant insider selling has been recorded for AVII in the recent period.
Based on recent SEC filings, insider sentiment for AVII is bearish with an Insider Alignment Score of 26/100 and a net flow of -$6.7M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at AVI BIOPHARMA INC (AVII) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 20 insiders are actively trading AVII stock, having executed 161 transactions in the past 90 days. The most active insider is Capital Management Llc/ca Eastbourne (Executive), who has made 5 transactions totaling $5.6M.
Get notified when executives and directors at AVII file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Apr 24, 2012 | Garabedian Christopher Nishan | Executive | Award | 81,666 | $N/A | $0 | |
| Mar 14, 2012 | Gil Price Ben | Executive | Purchase | 30,000 | $1.30 | $39.0K | |
| Dec 15, 2011 | Garabedian Christopher Nishan | Executive | Purchase | 300,000 | $0.58 | $174.0K | |
| Sep 13, 2011 | R. Chase Anthony | Executive | Purchase | 20,000 | $1.20 | $24.0K | |
| Jun 21, 2011 | Kathleen Behrens M. | Executive | Award | 5,000 | $N/A | $0 | |
| Jun 21, 2011 | R. Chase Anthony | Executive | Award | 5,000 | $N/A | $0 | |
| Jun 21, 2011 | Alden Goolsbee William | Executive | Award | 5,000 | $N/A | $0 | |
| Jun 21, 2011 | Gil Price Ben | Executive | Award | 5,000 | $N/A | $0 | |
| Jun 21, 2011 | Lennart Rudolf Wigzell Hans | Executive | Award | 5,000 | $N/A | $0 | |
| Jun 21, 2011 | Hodgman John | Executive | Award | 5,000 | $N/A | $0 | |
| Apr 6, 2011 | Kathleen Behrens M. | Executive | Purchase | 100,000 | $1.50 | $150.0K | |
| Apr 6, 2011 | Garabedian Christopher Nishan | Executive | Purchase | 130,000 | $1.50 | $195.0K | |
| Apr 6, 2011 | Gil Price Ben | Executive | Purchase | 20,000 | $1.50 | $30.0K | |
| Aug 27, 2010 | David Boyle J. II | Executive | Purchase | 5,000 | $2.13 | $10.7K | |
| Aug 13, 2010 | Gil Price Ben | Executive | Purchase | 4,000 | $1.93 | $7.7K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 71 | $10.4M | 64.8% |
Purchase(P) | 46 | $3.7M | 22.8% |
Exercise(M) | 12 | $1.9M | 12.0% |
Award(A) | 30 | $54.1K | 0.3% |
Other(J) | 2 | $12.9K | 0.1% |
Insider selling pressure at AVI BIOPHARMA INC has increased, with 20 insiders executing 161 transactions across all time. Total sales of $10.4M significantly outpace purchases of $3.7M, resulting in a net outflow of $6.7M. This selling activity appears largely discretionary, which may warrant closer attention from investors.